Dasatinib + Quercetin (D+Q)
Aliases: D+Q · Senolytic combo
Last verified: 2026-09-23
The short version
The first senolytic combination — clears senescent ("zombie") cells: dasatinib (leukemia drug) + quercetin (flavonoid). Clinical trials for IPF, diabetic kidney disease, Alzheimer's. Status: in clinical trials. Dasatinib approved (leukemia); the combination is investigational.
Identity & type
- Molecular type
- mali molekul
- Origin
- The first senolytic combination — clears senescent ("zombie") cells: dasatinib (leukemia drug) + quercetin (flavonoid).
Mechanism of action
Transient inhibition of SCAP (senescent-cell anti-apoptotic pathways) → apoptosis of senescent cells.
Dosing & routes
Official / clinical context
No approved official document exists for Dasatinib + Quercetin (D+Q). Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials: D 100 mg + Q 1000 mg/day, 2–3 days per cycle, infrequent cycles. Rare experiences (only under supervision): some report "easier" movement and fewer chronic pains after a cycle; most of the community stays away due to dasatinib's seriousness.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Rare experiences (only under supervision): some report "easier" movement and fewer chronic pains after a cycle; most of the community stays away due to dasatinib's seriousness.
Protocol — official vs community
Official / label
Dasatinib is an approved BCR-ABL/SRC kinase inhibitor (100–140 mg/day in oncology). The D+Q senolytic combination (100 mg dasatinib + 1 g quercetin, two consecutive days, repeated in cycles) exists only in research studies.
- 01Research cycle: D 100 mg + Q 1,000 mg, day 1 and 2 of each cycle
Duration: Research protocols: cycles every 2–4 weeks, 3–9+ cycles total.
Every element of the human data is under research supervision; dasatinib is a serious oncology drug with real risks.
Community (anecdotal)
Mirrors the research cycle (D 100 mg + Q 1,000 mg ×2 days) with 'refill' intervals of 2–12 weeks in self-directed use.
- Cycle:
- 2–4 cycles per year is the saner end; monthly self-cycling is the reckless end.
- Break:
- The cycle IS the break — intermittent by design.
Self-administering a kinase inhibitor without CBC monitoring is where senolytic enthusiasm meets genuine hematologic risk.
Human evidence
Phase I/II (Mayo Clinic): reduced senescence markers; outcome efficacy still being tested.
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Dasatinib: pleural effusions, myelosuppression (with continuous use; intermittent milder).characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.